<DOC>
	<DOCNO>NCT01124799</DOCNO>
	<brief_summary>The purpose study evaluate potential effect TMC435 sensitivity skin towards exposure sunlight . TMC435 drug currently development treatment chronic hepatitis C virus infection . This study conduct healthy volunteer . Ciprofloxacin , commonly use antibiotic , use positive control drug know mildly increase skin sensitivity exposure sunlight . This study also evaluate level TMC435 ciprofloxacin blood circulation safety tolerability TMC435 .</brief_summary>
	<brief_title>TMC435-TiDP16-C125 - Study Healthy Volunteers Evaluate Potential TMC435 Increase Sensitivity Skin Towards Exposure Sun Light</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double blind ( neither study doctor , medical staff healthy volunteer know name assign drug ) , double-dummy ( healthy volunteer take number identically look capsule , independent drug assign ) , placebo- positive-controlled ( ciprofloxacin drug know cause mild photosensitive response ) study . A total 36 healthy volunteer participate . Participants assign take TMC435 ( one dose 75 150 mg , day ) , TMC435-placebo ( day ) ciprofloxacin ( 500 mg twice day ) . The aim study look reaction skin exposure artificial sunlight take TMC435 , ciprofloxacin placebo . Study drug administer 9 day . Phototesting ( area skin back expose artificial sunlight ) conduct 3 day intake study medication start 3 day ( Days 8 , 9 10 ) treatment . Skin reaction , general tolerability safety TMC435 assess throughout trial period ( longer need ) . Blood urine sample take screening , day 1 , day 7 , day 10 2 follow-up visit . Blood level TMC435 ciprofloxacin determine Day 1 , 5 , 6 , 7 ( 16 time ) , 8 ( twice ) , 9 ( twice ) 10 . ECG vital sign take screening , day 1 , twice day 7 , day 10 2 follow-up visit . A physical examination do screening , day 1 , day 10 follow-up visit . Volunteers assign TMC435 group receive morning oral dose ( dose 75 150 mg ) TMC435 noon even oral dose placebo , 9 consecutive day . Volunteers assign placebo group receive oral placebo dos morning , noon evening , 9 consecutive day . Volunteers assign ciprofloxacin group receive oral morning placebo dose noon even oral dose 500 mg ciprofloxacin , 9 consecutive day .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Skin type I III No ultraviolet exposure back 4 week prior baseline phototesting Normal skin response baseline phototesting Body Mass Index 18.0 30.0 kg/m2 Healthy base medical evaluation include medical history , physical examination , blood test electrocardiogram . History hypersensitivity sunlight artificial source intense light , especially UV light history currently active porphyria lupus erythematosus Positive plasma porphyrin scan lupus erythematosus antibody Active skin disorder back phototesting perform Infection Hepatitis A , B C virus Infection human immunodeficiency virus ( HIV ) Women pregnant breastfeed History current medical condition could impact safety participant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Hepatitis C virus</keyword>
	<keyword>TMC435-TiDP16-C125</keyword>
	<keyword>TMC435-C125</keyword>
	<keyword>TMC435</keyword>
	<keyword>TMC435350</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>photosensitivity</keyword>
	<keyword>phototoxicity</keyword>
</DOC>